Actively Recruiting
Intralesional Injection of STS in Treatment of Calcinosis
Led by Robyn T. Domsic, MD, MPH · Updated on 2026-05-05
20
Participants Needed
1
Research Sites
215 weeks
Total Duration
On this page
Sponsors
R
Robyn T. Domsic, MD, MPH
Lead Sponsor
N
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.
CONDITIONS
Official Title
Intralesional Injection of STS in Treatment of Calcinosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of systemic sclerosis, mixed connective tissue disease or inflammatory myopathy
- Must be over 18 years of age
- Participants must be competent to give informed consent
- Participants must have radiographic evidence (xray or ultrasound) of calcinosis
- Participants must need symptomatic relief
You will not qualify if you...
- Pregnant women will be excluded
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UPMC Arthritis and Autoimmunity Center
Pittsburgh, Pennsylvania, United States, 15213
Actively Recruiting
Research Team
M
Maureen M Laffoon, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here